Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001437749-20-023028
Filing Date
2020-11-06
Accepted
2020-11-06 17:07:18
Documents
2
Period of Report
2020-11-04

Document Format Files

Seq Description Document Type Size
1 FORM 3 rdgdoc.html 3  
1 FORM 3 rdgdoc.xml 3 6974
2 kaufman_poa.htm EX-24 6677
  Complete submission text file 0001437749-20-023028.txt   15119
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Issuer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 4995 BRADENTON AVE SUITE 240 DUBLIN OH 43017
Business Address
Kaufman Joel H. (Reporting) CIK: 0001831425 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35076 | Film No.: 201295239